Last reviewed · How we verify
CYT003-QbG10
CYT003-QbG10 is a therapeutic vaccine designed to treat autoimmune diseases by modulating the immune response.
CYT003-QbG10 is a therapeutic vaccine designed to treat autoimmune diseases by modulating the immune response. Used for Relapsing-remitting multiple sclerosis, Rheumatoid arthritis.
At a glance
| Generic name | CYT003-QbG10 |
|---|---|
| Sponsor | Cytos Biotechnology AG |
| Drug class | Therapeutic vaccine |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
It works by inducing regulatory T cells to suppress the activity of autoreactive T cells, thereby reducing inflammation and tissue damage. This mechanism is thought to be beneficial in treating conditions such as multiple sclerosis and rheumatoid arthritis.
Approved indications
- Relapsing-remitting multiple sclerosis
- Rheumatoid arthritis
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (PHASE1, PHASE2)
- Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer (PHASE2)
- CMP-001 for Relapsed and Refractory Lymphoma (PHASE1, PHASE2)
- CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma (PHASE2)
- CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids (PHASE2)
- A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis (PHASE2)
- CYT003-QbG10 for Treatment of Allergic Asthma Bronchial (PHASE2)
- Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYT003-QbG10 CI brief — competitive landscape report
- CYT003-QbG10 updates RSS · CI watch RSS
- Cytos Biotechnology AG portfolio CI